Are you Xiang Fei?

Claim your profile

Publications (6)9.43 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: To better understand the contribution of dysregulated DNA methyltransferase 1 (DNMT1) expression to the progression and biology of clear cell renal cell carcinoma (ccRCC).
    08/2014; 26(4):371-81.
  • Yan Song, Xiang Fei, Yongsheng Song
    [Show abstract] [Hide abstract]
    ABSTRACT: OBJECTIVE: To review the management of problematic ureteral calculi in pregnancy and to compare efficacy among 3 treatments: ureteroscopic lithotripsy, ureteral stent insertion, and percutaneous nephrostomy. METHODS: In a retrospective study at Sheng Jing Hospital, Shenyang, China, data were analyzed from 54 consecutive pregnant patients who required medical intervention for urolithiasis between April 2001 and July 2012. The patients were divided into 3 groups based on whether they had ureteroscopic lithotripsy (group 1, n=21), nephrostomy (group 2, n=16), or ureteral stent insertion (group 3, n=17). Statistical significance was evaluated by Student t test and χ2 test. RESULTS: In group 1, 18 of 21 patients had complete calculi fragmentation. In group 2, nephrostomy was carried out successfully for all 16 patients. The insertion of a ureteral stent was possible for 12 of 17 patients in group 3. The ureteroscopic lithotripsy procedure took longer than the other 2 procedures (P<0.005). Patients in the stent insertion group had the highest rate of complications (52.9%) and lowest rate of success (70.6%). CONCLUSION: Ureteroscopic lithotripsy was found to be an effective intervention during pregnancy. However, the choice of treatment depends on the individual situation.
    International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics 03/2013; · 1.41 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The aims of this study were to determine the methylation and expression status of secreted Frizzled-related protein 1 (SFRP1) in bladder cancer, to explore the mechanisms involved and to study the role of SFRP1 in the pathogenesis of bladder cancer. SFRP1 mRNA was detected by reverse transcription PCR (RT-PCR). The DNA methylation status was determined by methylation-specific PCR and protein was detected using western blotting. The results of the present study demonstrated that SFRP1 was methylated in the bladder cancer cell lines T24 and 5637, but not in SCaBER cells. After treating T24 and 5637 cells with a demethylating agent, the cells expressed SFRP1 mRNA and protein. Among the 45 patients with bladder cancer, methylation of SFRP1 was detected in 28 patients (62.2%). Of the matched cancer-adjacent tissues, 6 (13.3%) were found to have methylated SFRP1. The result is statistically significant (P<0.01). In conclusion, SFRP1 is downregulated in certain bladder cancer patients as a consequence of methylation. SFRP1 methylation may be involved in the pathogenesis of bladder cancer via excessive activation of the Wnt signaling pathway.
    Oncology letters 08/2012; 4(2):334-338. · 0.24 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: It has been reported that expression of glucose transporter member 3 (GLUT3) is up-regulated in bladder cancers. However, the regulating mechanism remains unknown. Here, we assessed whether microRNAs (miRNAs) regulate GLUT3 expression in bladder cancers. In our study, miR-195-5p was identified to directly targeted GLUT3 3'-untranslated region (UTR) in bladder cancer T24 cells. Small interfering RNA (siRNA)- and miR-195-5p-mediated GLUT3 knockdown experiments revealed that miR-195-5p decreased T24 cells glucose uptake, inhibited cell growth and promoted cell apoptosis through suppression of GLUT3 expression. Therefore, miR-195-5p is a novel and also the first identified miRNA that targets GLUT3, and the aberrant decreased expression of miR-195-5p and consequent GLUT3 up-regulation may contribute to bladder carcinogenesis.
    FEBS letters 02/2012; 586(4):392-7. · 3.54 Impact Factor
  • Yan Song, Xiang Fei, Yongsheng Song
    [Show abstract] [Hide abstract]
    ABSTRACT: The aims of this study were to evaluate the efficacy of retrograde ureteral stenting and to identify the predictive factors for potential failure of this technique in women with advanced gynecologic malignancies. From 2006 to 2010, a retrospective analysis was performed on a total of 75 patients with ureteral obstruction due to gynecologic malignancies. This population was divided into group 1 (n = 50) in which retrograde stent placement was successful, and group 2 (n = 25) in which stent placement failed and subsequent percutaneous nephrostomy tube placement was required. Multivariate analysis was done to identify predictors of the failure of ureteral stent insertion. Multivariate analysis revealed that mean preprocedureal serum cystanin C greater than 2.5 mg/L and length of the ureteral obstruction greater than 3 cm were significant predictors of stent failure. Neither the causes nor location of obstruction predicted the need for percutaneous nephrostomy (PCN). No statistical significance was detected among the subgroups of patients with different degrees of hydronephrosis. Statistical significant differences were found between the 2 groups in procedural time, average cost, and mean interval of stent/catheter replacement. However, no statistically significant difference was found in the median survival time and overall stent-related or catheter-related complications between the 2 groups. Retrograde ureteral stenting is a first-line option for managing ureteral obstruction caused by gynecologic malignancies. However, in cases where the preprocedureal mean serum cystanin C is greater than 2.5 mg/L and the length of the ureteral obstruction segment is greater than 3 cm, these patients may be better served by percutaneous drainage.
    International Journal of Gynecological Cancer 02/2012; 22(4):697-702. · 1.94 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Unstable, gene-rich pericentric regions have been associated with various structural aberrations including small supernumerary marker chromosomes (sSMCs). We hereby report on a complex pure mosaic sSMCs derived from chromosomes 11 and 19 in a child featuring multiple congenital anomalies. As indicated by microarray analysis, the sSMCs have involved materials from 11p11.12 → q12.1 and 19p12 → q12 in complex forms (with four cell lines harboring from 1 to 4 sSMCs) in all peripheral blood lymphocytes. The patient featured facial dysmorphism, generalized hypotonia, cryptorchidism, transverse palmar creases, cerebral hemorrhage, atrial septal defect secundum, strabismus, epilepsy, immunodeficiency, and severe cognitive and motor impairment. Literature review indicated this to be a unique sSMCs case simultaneously involving chromosomes 11 and 19, with one sSMC containing materials from the both chromosomes. We propose that the involved chromosomal regions may contain dosage-sensitive genes which are important for the development, and that the sSMCs derived from multiple origins have formed by a complex mechanism.
    American Journal of Medical Genetics Part A 11/2011; 155A(12):3116-21. · 2.30 Impact Factor